Testing D-2570 tablets for moderate to severe plaque psoriasis in adults
Tests D-2570 tablets against placebo in adults with moderate to severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Birmingham, Chula Vista, Clarksville, Fort Lauderdale, Fountain Valley, Fremont, Idaho Falls, Los Angeles, Louisville, Mayfield Heights, Miramar, Ocala, Philadelphia, Phoenix, San Antonio, San Diego, Sandy Springs, Savannah, and Tampa, United StatesSee the 19 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07489885, who can take part
Where in United States
- BirminghamBirmingham, United StatesTaking people
- Chula VistaChula Vista, United StatesTaking people
- ClarksvilleClarksville, United StatesNot yet recruiting
- Fort LauderdaleFort Lauderdale, United StatesNot yet recruiting
- Fountain ValleyFountain Valley, United StatesNot yet recruiting
- FremontFremont, United StatesNot yet recruiting
- Idaho FallsIdaho Falls, United StatesNot yet recruiting
- Los AngelesLos Angeles, United StatesNot yet recruiting
- LouisvilleLouisville, United StatesNot yet recruiting
- Mayfield HeightsMayfield Heights, United StatesNot yet recruiting
- MiramarMiramar, United StatesNot yet recruiting
- OcalaOcala, United StatesNot yet recruiting
- PhiladelphiaPhiladelphia, United StatesNot yet recruiting
- PhoenixPhoenix, United StatesNot yet recruiting
- San AntonioSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesNot yet recruiting
- Sandy SpringsSandy Springs, United StatesNot yet recruiting
- SavannahSavannah, United StatesNot yet recruiting
- TampaTampa, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- InventisBio Co., Ltd
- Trial code
- NCT07489885
- Record updated
- 9 July 2026
- Original description
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque PsoriasisRead full original descriptionShow less
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Inclusion: Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent; Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3; Within normal ranges of laboratory assessments.
Exclusion: Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator.